Gene editing has moved from theory to bedside with a speed that would have seemed impossible a decade ago. A new wave of ...

A new CRISPR approach can control genes without cutting DNA, opening a safer path for treating genetic diseases. A newly ...

2023 was the year that CRISPR gene-editing sliced its way out of the lab and into the public consciousness—and American medical system. The Food and Drug Administration recently approved the first ...

The United Kingdom has become the first country to give regulatory approval to a medical treatment involving the revolutionary CRISPR gene editing tool. The country’s Medicines and Healthcare products ...

Gene therapy has always held enormous promise to correct genetic diseases, but turning that potential into treatments has been challenging. In the latest case, the scientists developed a CRISPR ...

Casgevy is now active across 35 Advanced Treatment Centres. Crispr Therapeutics 40% share in Casgevy could result in revenue annual between $1.2 billion and $2.8 billion towards the end of the decade.

TheFly published on November 26, 2025, that Chardan kept its buy recommendation on CRISPR Therapeutics AG (NASDAQ:CRSP) while ...

Depending on a forthcoming decision by the Food and Drug Administration, a treatment called CRISPR may be the next step toward giving those with sickle cell the hope of a pain-free life. Next, ...

Rare genetic diseases are challenging for patients and their families—made all the more overwhelming because symptoms tend to appear soon after birth. To date, there haven’t been many reliable ...

Red blood cells viewed through a microscope. The arrow points to a cell with the sickle-shaped malformation indicative of sickle cell disease, which is caused by a genetic abnormality. Credit: CDC/Dr.

CRISPR Therapeutics’ stock has climbed this year as investors await potential approvals of what may become the company’s first product. A positive regulatory decision in the U.S. could set the company ...